NewslettersMuscle Cell News BioJiva Reports Results of Pilot Phase II Clinical Trial of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS) By Bob - September 19, 2022 0 BioJiva reported data from its completed multicenter, randomized, double-blind, placebo-controlled pilot Phase II clinical trial evaluating RT001, the company’s lead development candidate, in patients with ALS. [BioJiva] Press Release